Mefloquine neurotoxicity: A literature review

Travel Medicine and Infectious Disease

Volumn 7, Issue 1, 2009, Pages 2-6

  Toovey, Stephen ^a  

^a Academic Centre for Travel Medicine and Vaccines   (United Kingdom)

Author keywords

Malaria; Mefloquine; Neuropsychiatric; Neurotoxicity; Ototoxicity; Prophylaxis

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; CHLOROQUINE; CHOLINESTERASE; HYDROXYCHLOROQUINE; MEFLOQUINE; QUINOLONE DERIVATIVE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ANXIETY; ARTICLE; BODY MASS; CALCIUM HOMEOSTASIS; CENTRAL NERVOUS SYSTEM; DISEASE EXACERBATION; DIZZINESS; DRUG ACCUMULATION; DRUG RECEPTOR BINDING; DRUG TRANSPORT; ENZYME BINDING; ENZYME INHIBITION; HUMAN; MULTIDRUG RESISTANCE; NAUSEA; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; PSYCHOPATHY; PSYCHOSIS; RISK ASSESSMENT; SEX DIFFERENCE; SIDE EFFECT; SLEEP DISORDER;

ANIMALS; ANTIMALARIALS; ARTEMISININS; BODY MASS INDEX; CENTRAL NERVOUS SYSTEM; FEMALE; MALE; MEFLOQUINE; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SEX FACTORS;

EID: 58549090904     PISSN: 14778939     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmaid.2008.12.004     Document Type: Article

References (82)

1. van Nassauw L., Toovey S., Van Op den Bosch J., Timmermans J.P., and Vercruysse J. Schistosomicidal activity of the antimalarial drug, mefloquine, in Schistosoma mansoni-infected mice. Travel Med Infect Dis 6 5 (2008) 253-258
2. Lydersen K. Family blames soldier's suicide on anti-malaria drug. Washington Post A10 (2008 Oct 12)
3. Bernard J., Le C.J., Sarrouy J., Renaudineau J., Geffray L., Dufour P., et al. [Toxic encephalopathy caused by mefloquine?]. Presse Med 16 33 (1987) 1654-1655
4. Ronn A.M., Ronne-Rasmussen J., Gotzsche P.C., and Bygbjerg I.C. Neuropsychiatric manifestations after mefloquine therapy for Plasmodium falciparum malaria: comparing a retrospective and a prospective study. Trop Med Int Health 3 2 (1998) 83-88
5. Caillon E., Schmitt L., and Moron P. Acute depressive symptoms after mefloquine treatment. Am J Psychiatry 149 5 (1992) 712
6. Dankwa E., and Martin P. Review on adverse events associated with lariam (mefloquine) (1997), Switzerland, Hoffmann-La Roche Ltd, Basel Period: January 1 to December 31, 1996
7. Harinasuta T., Bunnag D., and Wernsdorfer W.H. A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand. Bull World Health Organ 61 2 (1983) 299-305
8. Hennequin C., Bouree P., Bazin N., Bisaro F., and Feline A. Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine. Arch Intern Med 154 20 (1994) 2360-2362
9. Kofi Ekue J.M., Ulrich A.M., Rwabwogo-Atenyi J., and Sheth U.K. A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria. Bull World Health Organ 61 4 (1983) 713-718
10. Lebain P., Juliard C., Davy J.P., and Dollfus S. [Neuropsychiatric symptoms in preventive antimalarial treatment with mefloquine: apropos of 2 cases]. Encephale 26 4 (2000) 67-70
11. Luxemburger C., Nosten F., ter Kuiile F., Frejacques L., Chongsuphajaisiddhi T., and White N.J. Mefloquine for multidrug-resistant malaria. Lancet 338 8777 (1991) 1268
12. Mai N.T.H., Chuong L.V., Phu N.H., Hien T.T., Day N.P.J., Waller D., et al. Post-malaria neurological syndrome. Lancet 348 9032 (1996) 917-921
13. Marsepoil T., Petithory J., Faucher J.M., Ho P., Viriot E., and Benaiche F. [Encephalopathy and memory disorders during treatments with mefloquine]. Rev Med Interne 14 8 (1993) 788-791
14. Meier C.R., Wilcock K., and Jick S.S. The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Saf 27 3 (2004) 203-213
15. Patchen L.C., Campbell C.C., and Williams S.B. Neurologic reactions after a therapeutic dose of mefloquine. N Engl J Med 321 20 (1989) 1415-1416
16. Ronn A.M., and Bygbjerg I.C. [Acute brain syndrome after mefloquine treatment]. Ugeskr Laeger 156 41 (1994) 6044-6045
17. Rouveix B., Bricaire F., Michon C., Franssen G., Lebras J., Bernard J., et al. Mefloquine and an acute brain syndrome. Ann Intern Med 110 7 (1989) 577-578
18. Sowunmi A., Salako L.A., Oduola A.M., Walker O., Akindele J.A., and Ogundahunsi O.A. Neuropsychiatric side effects of mefloquine in Africans. Trans R Soc Trop Med Hyg 87 4 (1993) 462-463
19. Sowunmi A., Adio R.A., Oduola A.M., Ogundahunsi O.A., and Salako L.A. Acute psychosis after mefloquine. Report of six cases. Trop Geogr Med 47 4 (1995) 179-180
20. Speich R., and Haller A. Central anticholinergic syndrome with the antimalarial drug mefloquine. N Engl J Med 331 1 (1994) 57-58
21. Stuiver P.C., Ligthelm R.J., and Goud T.J. Acute psychosis after mefloquine. Lancet 2 8657 (1989) 282
22. van Riemsdijk M.M., Sturkenboom M.C., Ditters J.M., Ligthelm R.J., Overbosch D., and Stricker B.H. Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. Clin Pharmacol Ther 72 3 (2002) 294-301
23. van Riemsdijk M.M., Ditters J.M., Sturkenboom M.C., Tulen J.H., Ligthelm R.J., Overbosch D., et al. Neuropsychiatric events during prophylactic use of mefloquine before travelling. Eur J Clin Pharmacol 58 6 (2002) 441-445
24. Wittes R.C., and Saginur R. Adverse reaction to mefloquine associated with ethanol ingestion. CMAJ 152 4 (1995) 515-517
25. Ajana F., Fortier B., Martinot A., Rouveix B., and Camus D. Mefloquine prophylaxis and neurotoxicity - report of a case. Sem Hop 66 17 (1990) 918-919
26. Dow G., Bauman R., Caridha D., Cabezas M., Du F., Gomez-Lobo R., et al. Mefloquine induces dose-related neurological effects in a rat model. Antimicrob Agents Chemother 50 3 (2006) 1045-1053
27. Nicolas X., Granier H., Laborde J.P., Martin J., and Talarmin F. Danger of self-administered malaria prophylaxy. Presse Med 30 27 (2001) 1349-1350
28. Borruat F.X., Nater B., Robyn L., and Genton B. Prolonged visual illusions induced by mefloquine (LariamR): a case report. J Travel Med 8 3 (2001) 148-149
29. Lobel H.O., Baker M.A., Gras F.A., Stennies G.M., Meerburg P., Hiemstra E., et al. Use of malaria prevention measures by North American and European travelers to East Africa. J Travel Med 8 4 (2001) 167-172
30. Petersen E., Ronne T., Ronn A., Bygbjerg I., and Larsen S.O. Reported side effects to chloroquine, chloroquine plus proguanil, and mefloquine as chemoprophylaxis against malaria in Danish travelers. J Travel Med 7 2 (2000) 79-84
31. Schlagenhauf P., Steffen R., Lobel H., Johnson R., Letz R., Tschopp A., et al. Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health 1 4 (1996) 485-494
32. Schlagenhauf P., Tschopp A., Johnson R., Nothdurft H.D., Beck B., Schwartz E., et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ 327 7423 (2003) 1078
33. Brumbaugh M., Price P., Fagan N., and Hsieh H. Psychotic mania associated with mefloquine in a bipolar patient. South Med J 101 5 (2008) 550-551
34. Fujii T., Kaku K., Jelinek T., and Kimura M. Malaria and mefloquine prophylaxis use among Japan Ground Self-Defense Force personnel deployed in East Timor. J Travel Med 14 4 (2007) 226-232
35. Jousset N., Guilleux M., de Gentile L., Le Bouil A., Turcant A., and Rouge-Maillart C. [Spectacular suicide associated with mefloquine]. Presse Med 35 5 Pt 1 (2006) 789-792
36. Tran T.M., Browning J., and Dell M.L. Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report. Malar J 5 (2006) 74
37. Steffen R., Fuchs E., Schildknecht J., Naef U., Funk M., Schlagenhauf P., et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 341 8856 (1993) 1299-1303
38. Potasman I., Beny A., and Seligmann H. Neuropsychiatric problems in 2,500 long-term young travelers to the tropics. J Travel Med 7 1 (2000) 5-9
39. Schlagenhauf P., and Steffen R. Neuropsychiatric events and travel: do antimalarials play a role?. J Travel Med 7 5 (2000) 225-226
40. Overbosch D. Post-marketing surveillance: adverse events during long-term use of atovaquone/proguanil for travelers to malaria-endemic countries. J Travel Med 10 Suppl 1 (2003) S16-S20
41. van Riemsdijk M.M., Sturkenboom M.C., Ditters J.M., Tulen J.H., Ligthelm R.J., Overbosch D., et al. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol 57 4 (2004) 506-512
42. Ollivier L., Tifratene K., Josse R., Keundjian A., and Boutin J.P. The relationship between body weight and tolerance to mefloquine prophylaxis in non-immune adults: results of a questionnaire-based study. Ann Trop Med Parasitol 98 6 (2004) 639-641
43. Davis T.M., Dembo L.G., Kaye-Eddie S.A., Hewitt B.J., Hislop R.G., and Batty K.T. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 42 4 (1996) 415-421
44. Vuurman E.F., Muntjewerff N.D., Uiterwijk M.M., van Veggel L.M., Crevoisier C., Haglund L., et al. Effects of mefloquine alone and with alcohol on psychomotor and driving performance. Eur J Clin Pharmacol 50 6 (1996) 475-482
45. Schlagenhauf P., Lobel H., Steffen R., Johnson R., Popp K., Tschopp A., et al. Tolerance of mefloquine by SwissAir trainee pilots. Am J Trop Med Hyg 56 2 (1997) 235-240
46. Fusetti M., Eibenstein A., Corridore V., Hueck S., and Chiti-Batelli S. [Mefloquine and ototoxicity: a report of 3 cases]. Clin Ter 150 5 (1999) 379-382
47. Wise M., and Toovey S. Reversible hearing loss in temporal association with chemoprophylactic mefloquine use. Travel Med Infect Dis 5 6 (2007) 385-388
48. Hessen-Soderman A.C., Bergenius J., Palme I.B., Bergqvist Y., and Hellgren U. Mefloquine prophylaxis and hearing, postural control, and vestibular functions. J Travel Med 2 2 (1995) 66-69
49. Berninger E., Karlsson K.K., and Alvan G. Quinine reduces the dynamic range of the human auditory system. Acta Otolaryngol 118 1 (1998) 46-51
50. Claessen F.A.P., van Boxtel C.J., Perenboom R.M., Tange R.A., Wetsteijn J.C.F.M., and Kager P.A. Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy Caucasian subjects and in patients with falciparum malaria. Trop Med Int Health 3 6 (1998) 482-489
51. 2+ channel antagonist verapamil. Acta Otolaryngol 117 1 (1997) 46-48
52. Karlsson K.K., Hellgren U., Alvan G., and Rombo L. Audiometry as a possible indicator of quinine plasma concentration during treatment of malaria. Trans R Soc Trop Med Hyg 84 6 (1990) 765-767
53. Karlsson K.K., Berninger E., and Alvan G. The effect of quinine on psychoacoustic tuning curves, stapedius reflexes and evoked otoacoustic emissions in healthy volunteers. Scand Audiol 20 2 (1991) 83-90
54. Toovey S. Are currently deployed artemisinins neurotoxic?. Toxicol Lett 166 2 (2006) 95-104
55. Lo S.H., Kotabe S., and Mitsunaga L. Azithromycin-induced hearing loss. Am J Health Syst Pharm 56 4 (1999) 380-383
56. Mamikoglu B., and Mamikoglu O. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report. Ann Otol Rhinol Laryngol 110 1 (2001) 102
57. Ress B.D., and Gross E.M. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report. Ann Otol Rhinol Laryngol 109 4 (2000) 435-437
58. Taylor W.R., Richie T.L., Fryauff D.J., Ohrt C., Picarima H., Tang D., et al. Tolerability of azithromycin as malaria prophylaxis in adults in northeast Papua, Indonesia. Antimicrob Agents Chemother 47 7 (2003) 2199-2203
59. Hadi U., Nuwayhid N., and Hasbini A.S. Chloroquine ototoxicity: an idiosyncratic phenomenon. Otolaryngol Head Neck Surg 114 3 (1996) 491-493
60. Coutinho M.B., and Duarte I. Hydroxychloroquine ototoxicity in a child with idiopathic pulmonary haemosiderosis. Int J Pediatr Otorhinolaryngol 62 1 (2002) 53-57
61. Johansen P.B., and Gran J.T. Ototoxicity due to hydroxychloroquine: report of two cases. Clin Exp Rheumatol 16 4 (1998) 472-474
62. Seckin U., Ozoran K., Ikinciogullari A., Borman P., and Bostan E.E. Hydroxychloroquine ototoxicity in a patient with rheumatoid arthritis. Rheumatol Int 19 5 (2000) 203-204
63. Barrenas M.L. The influence of a melanin-binding drug on temporary threshold shift in humans. Scand Audiol 23 2 (1994) 93-98
64. Barrenas M.L. Hair cell loss from acoustic trauma in chloroquine-treated red, black and albino guinea pigs. Audiology 36 4 (1997) 187-201
65. Barrenas M.L., and Holgers K.M. Ototoxic interaction between noise and pheomelanin: distortion product otoacoustic emissions after acoustical trauma in chloroquine-treated red, black, and albino guinea pigs. Audiology 39 5 (2000) 238-246
66. Dow G.S., Hudson T.H., Vahey M., and Koenig M.L. The acute neurotoxicity of mefloquine may be mediated through a disruption of calcium homeostasis and ER function in vitro. Malar J 2 (2003) 14
67. Toovey S., Bustamante L.Y., Uhlemann A.C., East J.M., and Krishna S. Effect of artemisinins and amino alcohol partner antimalarials on mammalian sarcoendoplasmic reticulum calcium adenosine triphosphatase activity. Basic Clin Pharmacol Toxicol 103 3 (2008) 209-213
68. Shepard R.D., and Fletcher A. Use of (+)-mefloquine for the treatment of malaria with reduced side-effects. Int Patent Appl WO 9839003 (1998)
69. Ngiam T.L., and Go M.L. Stereospecific inhibition of cholinesterases by mefloquine enantiomers. Chem Pharm Bull (Tokyo) 35 1 (1987) 409-412
70. Zhou C., Xiao C., McArdle J.J., and Ye J.H. Mefloquine enhances nigral gamma-aminobutyric acid release via inhibition of cholinesterase. J Pharmacol Exp Ther 317 3 (2006) 1155-1160
71. Margineanu D.G., and Klitgaard H. The connexin 36 blockers quinine, quinidine and mefloquine inhibit cortical spreading depression in a rat neocortical slice model in vitro. Brain Res Bull 71 1-3 (2006) 23-28
72. Cruikshank S.J., Hopperstad M., Younger M., Connors B.W., Spray D.C., and Srinivas M. Potent block of Cx36 and Cx50 gap junction channels by mefloquine. Proc Natl Acad Sci U S A 101 33 (2004) 12364-12369
73. Gribble F.M., Davis T.M., Higham C.E., Clark A., and Ashcroft F.M. The antimalarial agent mefloquine inhibits ATP-sensitive K-channels. Br J Pharmacol 131 4 (2000) 756-760
74. Pham Y.T., Nosten F., Farinotti R., White N.J., and Gimenez F. Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. Int J Clin Pharmacol Ther 37 1 (1999) 58-61
75. Eckstein-Ludwig U., Webb R.J., Van Goethem I.D., East J.M., Lee A.G., Kimura M., et al. Artemisinins target the SERCA of. Plasmodium falciparum. Nature 424 6951 (2003) 957-961
76. Basheer R., Strecker R.E., Thakkar M.M., and McCarley R.W. Adenosine and sleep-wake regulation. Prog Neurobiol 73 6 (2004) 379-396
77. Murillo-Rodriguez E., Blanco-Centurion C., Sanchez C., Piomelli D., and Shiromani P.J. Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study. Sleep 26 8 (2003) 943-947
78. De Sarro A., and De Sarro G. Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr Med Chem 8 4 (2001) 371-384
79. Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett 127 1-3 (2002) 269-277
80. Barraud de Lagerie S., Comets E., Gautrand C., Fernandez C., Auchere D., Singlas E., et al. Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice. Br J Pharmacol 141 7 (2004) 1214-1222
81. Aarnoudse A.L., van Schaik R.H., Dieleman J., Molokhia M., van Riemsdijk M.M., Ligthelm R.J., et al. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin Pharmacol Ther 80 4 (2006) 367-374
82. Toovey S., and Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 98 5 (2004) 261-267